Healthcare Sales & Marketing Network News: EGFr

Searching News Database: EGFr

HSMN NewsFeed - 24 Oct 2024
Pillar Biosciences Receives CPT(R) Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit
Diagnostics Oncology Reimbursement

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Aug 2024
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
Biopharmaceuticals

HSMN NewsFeed - 24 Jun 2024
Harmony Biosciences Receives U.S. Food And Drug Administration Approval For Wakix(R) (Pitolisant) In Pediatric Patients With Narcolepsy
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Mar 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 16 Feb 2024
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Jan 2024
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Aug 2023
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Jun 2023
Acepodia Secures $100 Million Series D Financing to Advance
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 6 Dec 2022
Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy
Diagnostics Biopharmaceuticals

HSMN NewsFeed - 15 Aug 2022
Alternative Pathway Blocker Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Efficacy Trial in C3 Glomerulopathy (C3G) Patients
Biopharmaceuticals FDA

HSMN NewsFeed - 18 May 2022
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Mar 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
Biopharmaceuticals

HSMN NewsFeed - 30 Dec 2021
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 29 Nov 2021
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 1 Nov 2021
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Aug 2021
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
Biopharmaceuticals

HSMN NewsFeed - 26 Jul 2021
Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 May 2021
TricValve(R) Transcatheter Bicaval Valves System Receives CE Mark
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 13 Apr 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Feb 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Dec 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals

HSMN NewsFeed - 23 Dec 2020
Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Nov 2020
OrbusNeich(R) Medical and P+F Products & Features(R) announce new partnership
Devices Interventional Cardiology Distribution

HSMN NewsFeed - 29 Oct 2020
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 5 Oct 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 25 Aug 2020
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA

HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 May 2020
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals

HSMN NewsFeed - 27 Apr 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Apr 2020
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector(TM) Technology Validated for Use in Both Tissue and Blood Samples
Diagnostics Oncology Product Launch

HSMN NewsFeed - 6 Apr 2020
OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact(R) in Patients With Primary Hyperoxaluria
Biopharmaceuticals

HSMN NewsFeed - 1 Apr 2020
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Mar 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Dec 2019
Fluxion Launches Three New Spotlight(TM) Liquid Biopsy NGS Panels
Diagnostics Oncology Product Launch

HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Dec 2019
Black Diamond Therapeutics Closes $85 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 23 Sep 2019
FogPharma Expands Leadership Team with Key Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Sep 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 May 2019
U.S. FDA Approves GATTEX(R) (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 May 2019
Portage Announces Change of CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Mar 2019
Rakuten Aspyrian Announces Name Change to Rakuten Medical
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Feb 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Diagnostics Oncology Regulatory

HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jan 2019
Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA
Diagnostics Oncology Product Launch

HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Biopharmaceuticals Generics Oncology Regulatory

HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory

HSMN NewsFeed - 23 Aug 2018
Rakuten Aspyrian Raises $150 Million in Series C Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 23 Aug 2018
Roche receives FDA approval for cobas EGFR Mutation Test v2 as companion diagnostic with IRESSA (gefitinib) in first-line treatment of patients with non-small cell lung cancer (NSCLC)
Diagnostics Oncology FDA

HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jun 2018
Alpha Biopharma Announces Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Apr 2018
Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy
Biopharmaceuticals Oncology Drug Delivery Personnel

HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 9 Mar 2018
Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Mar 2018
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Feb 2018
closerlook, inc. names Steve Tulk as Chief Technology Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2017
Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology

HSMN NewsFeed - 23 Jun 2017
EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Jun 2017
Avant Diagnostics Appoints Philippe Goix, PhD, MBA as President & CEO to Commercialize Proprietary Theralink(R) Tumor Biomarker Platform
Diagnostics Oncology Personnel

HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 May 2017
Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of Directors
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Mar 2017
EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV(TM) Nanocells to Treat Glioblastoma Multiforme
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology

HSMN NewsFeed - 3 Aug 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA

HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Diagnostics Oncology Regulatory

HSMN NewsFeed - 1 Apr 2016
Taiho's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in Asian Patients with Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jan 2016
CARsgen Therapeutics Completes $30 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Nov 2015
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal(TM) (Thyroid microRNA Classifier)
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 21 Sep 2015
Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 2 Sep 2015
Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing
Diagnostics Venture Capital

HSMN NewsFeed - 29 May 2015
Transgenomic Launches EGFR CLIA Test That Accurately Detects Key Mutations in Solid and Liquid Patient Samples Using Multiplexed ICE COLD-PCR(TM)
Diagnostics Oncology Product Launch

HSMN NewsFeed - 26 May 2015
Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile
Diagnostics FDA

HSMN NewsFeed - 11 May 2015
Roche Receives FDA Approval for cobas(R) KRAS Mutation Test
Diagnostics Oncology FDA

HSMN NewsFeed - 6 Apr 2015
European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Mar 2015
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
Biopharmaceuticals Ophthalmology Oncology Personnel

HSMN NewsFeed - 19 Mar 2015
Coronado Biosciences Announces Exclusive Licensing Agreement With NeuPharma to Develop and Commercialize Novel Covalent 3rd Generation EGFR Inhibitors
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Feb 2015
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth Strategy
Diagnostics Personnel

HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jan 2015
Roche receives FDA clearance for next generation cobas MRSA/SA Test
Diagnostics FDA

HSMN NewsFeed - 2 Dec 2014
Oncolytics Biotech(R) Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Oct 2014
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 16 Oct 2014
FDA Approves Boehringer Ingelheim's OFEV(R) (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Aug 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
Biopharmaceuticals

HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Jun 2014
Tyrogenex Raises $15M in Series D Financing from Brace Pharma, US Investment Arm of EMS S/A
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 13 Jun 2014
EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals
Biopharmaceuticals

HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 May 2014
FDA Approves Conversion of Soliris(R) (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Apr 2014
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 24 Apr 2014
FDA Approves Roche's HPV Test for First-Line Primary Screening for Cervical Cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 7 Apr 2014
Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Mar 2014
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Feb 2014
Quest Diagnostics Expands Hereditary Cancer Screening Offering with Lynch Syndrome Blood and Biopsy Testing for Colorectal Cancer
Diagnostics Oncology Product Launch

HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jan 2014
U.S. FDA Approves Farxiga(TM) (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 23 Dec 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 17 Oct 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Oct 2013
IntegraGen Obtains Exclusive License for MicroRNA Which Predicts Therapy Outcomes in Metastatic Colorectal Cancer
Diagnostics Oncology Licensing

HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Aug 2013
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 5 Aug 2013
Affymetrix Launches New OncoScan(TM) FFPE Assay Kit
Diagnostics Oncology Product Launch

HSMN NewsFeed - 2 Jul 2013
FDA Grants Genentech’s Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology

HSMN NewsFeed - 20 May 2013
eFFECTOR Therapeutics Raises $45 Million in Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 20 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 May 2013
Curis Announces Approval of Erivedge(R) in Australia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Apr 2013
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Nov 2012
Clovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2012
Life Technologies Launches Pervenio(TM) Lung RS, a Risk Stratification Test for Early Stage Lung Cancer
Diagnostics Oncology

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 25 Jul 2012
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jul 2012
NeoGenomics Significantly Expands Molecular Testing Menu and Launches NeoTYPE(TM) Cancer Profile Panels
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 17 Jul 2012
Biodesix Appoints Vice President of Clinical Development & Medical Affairs
Diagnostics Personalized Medicine Personnel

HSMN NewsFeed - 22 Jun 2012
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s Perjeta
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2012
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Apr 2012
Trial of Medtronic Symplicity(TM) Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment
Devices Interventional Cardiology

HSMN NewsFeed - 27 Apr 2012
New Drug Application for Arzerra Submitted in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Apr 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Diagnostics FDA

HSMN NewsFeed - 27 Mar 2012
Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Mar 2012
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Nov 2011
Soliris(R) (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Sep 2011
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jul 2011
Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Mar 2011
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Dec 2010
Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women With Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Nov 2010
VeriStrat(R) Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2010
Celldex Therapeutics Regains Worldwide Rights to Rindopepimut (CDX-110)
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2010
Genentech Provides Update on FDA Application for T-DM1
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Jul 2010
Karen Lackey Named Vice President and Head of Medicinal Chemistry at Roche
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jul 2010
GTC Biotherapeutics Regains US Rights to ATryn(R) ; the First Recombinant Antithrombin Product Approved in the World
Biopharmaceuticals

HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jun 2010
Exelixis Regains Full Rights to Develop and Commercialize XL184
Biopharmaceuticals

HSMN NewsFeed - 16 Jun 2010
GTC Biotherapeutics Announces New $7 Million Financing, Company Restructuring and Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Mar 2010
Declaratory Relief Complaint for Patent Infringement Under Patent Based on Manufacture, Marketing and Sale of Arzerra
Biopharmaceuticals Oncology Litigation

HSMN NewsFeed - 22 Mar 2010
Asuragen Appoints French Distributor Biomedical Diagnostics SA for Signature(R) Oncology Portfolio
Diagnostics Oncology Distribution

HSMN NewsFeed - 19 Mar 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Feb 2010
Lilly, Merck, And Pfizer Join Forces To Accelerate Research And Improve Treatment Of Lung And Gastric Cancers In Asia
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Feb 2010
EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2010
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Jan 2010
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jan 2010
AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
Personalized Medicine Diagnostics Biopharmaceuticals

HSMN NewsFeed - 15 Jan 2010
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Nov 2009
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Nov 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Oct 2009
Declaratory Judgment Action Filed by GSK
Biopharmaceuticals Litigation

HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Sep 2009
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Sep 2009
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Aug 2009
Aperio Receives Second FDA Clearance for HER2 Image Analysis Application for Breast Cancer
Diagnostics Oncology FDA

HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jul 2009
AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jul 2009
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jun 2009
Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
Diagnostics Oncology

HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2009
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 May 2009
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 May 2009
Biodesix Advances the Field of Personalized Medicine With the Launch of VeriStrat(R)
Diagnostics Oncology

HSMN NewsFeed - 5 May 2009
Clarient Launches New Breast Cancer Test
Diagnostics Oncology

HSMN NewsFeed - 24 Apr 2009
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Apr 2009
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Feb 2009
Warnex Offers New Personalized Medicine Service: K-ras Mutation Analysis for Colorectal Cancer
Diagnostics Oncology

HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology

HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Nov 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Nov 2008
NCCN Updates Guidelines for Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Jul 2008
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jul 2008
Nexavar Approved for Liver Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Jul 2008
European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel(R) for Patients With Moderate-to-Severe Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Jul 2008
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Biopharmaceuticals Radiology FDA

HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 1 Jul 2008
Clarient Launches New Colorectal Cancer Test
Diagnostics Oncology

HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2008
Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 May 2008
AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
Biopharmaceuticals Licensing

HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Apr 2008
ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Apr 2008
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Mar 2008
Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Mar 2008
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Mar 2008
Curis Announces Conclusion of Hedgehog Agonist Collaboration with Wyeth
Biopharmaceuticals

HSMN NewsFeed - 7 Mar 2008
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
Diagnostics Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Feb 2008
YM Biosciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Feb 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Jan 2008
KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2008
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Dec 2007
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Dec 2007
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Nov 2007
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
Biopharmaceuticals

HSMN NewsFeed - 19 Nov 2007
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Nov 2007
NCCN Receives Major Grant for Anti-Cancer Drug Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Nov 2007
Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
Biopharmaceuticals Cardiology

HSMN NewsFeed - 1 Nov 2007
AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Oct 2007
NCCN Updates Non-Small Cell Lung Cancer Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2007
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Oct 2007
OSI Pharmaceuticals Provides Additional Information about US Sales of Tarceva
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Oct 2007
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2007
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2007
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Sep 2007
Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Sep 2007
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmacetuicals Oncology

HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing

HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Aug 2007
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Aug 2007
Thanks to Portable Driver Available Only in Europe German Heart Institute Berlin Surpasses Highest Artificial Heart Implant Total
Devices Cardiology

HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Aug 2007
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Aug 2007
Oncoscience Ag, the European Partner of Ym Biosciences, Announces Completion of Patient Enrollment in Phase III Brain Cancer Trial of Nimotuzumab
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Aug 2007
Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions

HSMN NewsFeed - 19 Jul 2007
Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jul 2007
Adnexus Therapeutics Appoints Martin Freed, MD as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jun 2007
Genmab Regains Rights to HuMax-CD4
Biopharmaceuticals

HSMN NewsFeed - 27 Jun 2007
Cyclacel Pharmaceuticals Announces Appointment of Distinguished Pharma Executive as Senior Vice President, Research
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jun 2007
YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF(TM)
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jun 2007
OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jun 2007
Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Jun 2007
Genmab Announces Development Plans for Ofatumumab
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jun 2007
GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2007
OSI Pharmaceuticals Announces the Election of Kenneth B. Lee, Jr. to Its Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Jun 2007
Biodesix, Inc. Announces Breakthrough In Molecular Diagnostics For Lung Cancer
Diagnostics Oncology

HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Celldex Therapeutics Announces Updated EGFRvIII Vaccine Data in Glioblastoma Multiforme Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2007
Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2007
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Apr 2007
YM BioSciences' partner Daiichi Sankyo receives clearance for initial clinical trial in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Apr 2007
Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Apr 2007
KCI Investigators Present Breast Cancer Findings
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2007
YM BioSciences Strengthens Program Management of Lead Drugs
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Mar 2007
Amgen Discontinues Vectibix(TM) Treatment in Pacce Trial Evaluating Vectibix(Tm) as Part of Triple Combination Regimen
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Mar 2007
Exelixis Files IND Application for XL147
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Mar 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 13 Mar 2007
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R) (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Feb 2007
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Feb 2007
GSK Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Feb 2007
Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Feb 2007
YM BioSiences Announces Management Changes
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Feb 2007
Advanced Bio-Surfaces Reports Over 125 Successful Implants of the OrthoGlide(TM) Medial Knee Implant
Devices Orthopaedic

HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Feb 2007
ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
Biopharmaceuticals

HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jan 2007
OSI Pharmaceuticals Licenses Its Glucokinase Activator Program for the Treatment of Type 2 Diabetes to Eli Lilly and Company
Biopharmaceuticals Endocrinology Licensing

HSMN NewsFeed - 4 Jan 2007
AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 28 Dec 2006
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Dec 2006
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Dec 2006
OSI Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Dec 2006
OSI Pharmaceuticals Grants License to Bristol-Myers Squibb under Dipeptidyl Peptidase IV (DPIV) Patent Portfolio for the Treatment of Type 2 Diabetes
Biopharmaceuticals Licensing

HSMN NewsFeed - 13 Dec 2006
Lapatinib (Tykerb(R)) to be Evaluated in Early Stage Disease in Adjuvant Breast Cancer Settings Internationally
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Dec 2006
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Nov 2006
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Nov 2006
AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology

HSMN NewsFeed - 16 Oct 2006
Hana Biosciences Licenses Drug Candidate for the Prevention and Treatment of EGFR Inhibitor-Associated Skin Rash
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 4 Oct 2006
Dako Receives FDA Approval for Use of EGFR pharmDx(TM) With Vectibix(TM)
Diagnostics FDA Oncology

HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Sep 2006
Genmab Initiates HuMax-EGFr Pivotal Study In Refractory Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Jul 2006
YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Jul 2006
ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Jun 2006
Receptor BioLogix Names Thomas A. Glaze Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Jun 2006
YM Biosciences announces independent Data Safety Monitoring Board recommends tesmilifene pivotal trial continue as planned
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 21 Jun 2006
First AdNectin Therapeutic, CT-322, Clears FDA IND Review to Start Clinical Trials
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 25 May 2006
Advanced Bio-Surfaces(R) Announces Initial Experiences of OrthoGlide(TM) Medial Knee Implant
Devices Orthopaedic

HSMN NewsFeed - 24 May 2006
GlaxoSmithKline Demonstrates Progress of Oncology Portfolio; New Data to Be Presented at ASCO 2006
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology

Return to NewsFeed

Additional items found! 227

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 227 additional stories matching:
EGFr
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.